A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Hidradenitis Suppurativa
In brief
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Key facts
- Study ID
- NCT06799000
- Run by
- Novartis Pharmaceuticals
- People needed
- 588
- Starts
- 2025-01-31
- Expected to finish
- 2027-10-04
- Last updated by the study team
- 2026-05-22
Who can join
Age: 12 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Johnson Dermatology — Fort Smith, Arkansas, United States
- Arkansas Research Trials — North Little Rock, Arkansas, United States
- Cheryl Effron MD Inc — Anaheim, California, United States
- Physioseq — Sacramento, California, United States
- Olive View UCLA Medical Center — Sylmar, California, United States
- Clinical Trials Research Institute — Thousand Oaks, California, United States
- Howard University College of Medicine — Washington D.C., District of Columbia, United States
- Florida Academic Centers Research and Education LLC — Coral Gables, Florida, United States
- University of MiamiHealth System — Miami, Florida, United States
- Ziaderm Research LLC — North Miami Beach, Florida, United States
- Revival Research Institute LLC — Evans, Georgia, United States
- Gwinnett Clinical Research Center — Snellville, Georgia, United States
- Immunology-Rheumatology Research — Suwanee, Georgia, United States
- Illinois Dermatology Institute — Chicago, Illinois, United States
- Dawes Fretzin Clinical Rea Group — Indianapolis, Indiana, United States
- Equity Medical LLC — Bowling Green, Kentucky, United States
- Dermat. and Adv. Aesthetics — Lake Charles, Louisiana, United States
- Michigan Center for Rsrch Company — Clarkston, Michigan, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Revival Research Institute — Troy, Michigan, United States
- University of Mississippi Med Ctr — Jackson, Mississippi, United States
- Care Access Hoboken — Hoboken, New Jersey, United States
- Forest Hills Dermatology Group — New York, New York, United States
- Icahn School Of Med At Mount Sinai — New York, New York, United States
- Medical Dermatology Specialists — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.